Natixis’s Seres Therapeutics MCRB Stock Holding History

Natixis’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250	Closed	-$11.9K	–	1119
2023 Q3	$11.9K	Sell	250 -4,700	-95%	-$359K	﹤0.01%	888
2023 Q2	$474K	Buy	+4,950	New	+$539K	﹤0.01%	647

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Natixis's MCRB Position: Q4 2023 in Review

Natixis sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 250 shares — an estimated $11.9K sold.

Natixis first reported a position in MCRB in Q2 2023 and held it in 2 quarters. The position peaked at $474K in Q2 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

Natixis reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
Natixis sold 250 Seres Therapeutics shares in Q4 2023, an estimated $11.9K.
Natixis first reported a position in Seres Therapeutics in Q2 2023 and held it in 2 quarters.
Natixis's Seres Therapeutics position peaked at $474K in Q2 2023.
102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Natixis's 13F filing for Q4 2023, filed 13 Feb 2024.